Short answer: In the United States, the core patent protection on the infliximab molecule (Remicade) has largely expired, and Remicade has faced biosimilar competition for several years. In other jurisdictions (EU and elsewhere), patent coverage can still exist for certain aspects (e.g., formulations, manufacturing methods, specific uses) and data/exclusivity protections can apply differently. Because patent status is highly jurisdiction- and patent-family-specific, there isn’t a single global “Remicade patent status” for 2026.
If you want precise, current status for a particular market or aspect (composition of matter, formulation, manufacturing process, or use), here are the best sources to check:
- United States
- FDA Purple Book: lists licensure, exclusivity, and patent information for biological reference products.
- USPTO Patent Center: patent grants, expirations, and status.
- Be mindful of any remaining patent term extensions or litigation that could affect scope.
- European Union
- European Patent Office (Espacenet) / EU Patent Portal: patent families, expiry dates, and SPCs (Supplementary Protection Certificates).
- Global
- WIPO Patentscope for international patent families and status.
- Regulatory exclusivity
- US: 12-year data exclusivity for biologics under BPCIA (affects when a biosimilar can rely on reference data).
- EU: data protection periods for biologics differ by jurisdiction and can affect timing of biosimilar approvals.
If you’d like, tell me:
- Which market(s) you care about (US, EU, other),
- Whether you’re interested in composition-of-matter patents, formulation/manufacturing patents, or use patents,
- And whether you want a quick current snapshot or a step-by-step guide to perform a search.
I can tailor a more specific summary or walk you through how to pull the latest status from the official databases. If you’d like, I can also attempt to pull the latest public data for a particular jurisdiction if you want me to browse.